BioSpace News Archive

The global radiometric detectors market is expected to offer a comprehensive analysis of the respective market shares of leading market players, key strategies, and business models pertaining to the existing landscape.

An increase in the funding activities in the biotechnology sector coupled with the latest advancements in biological and chemical research will bring immense growth prospects for the laboratory supplies market during the forecast period of 2021-2031.

Cataract surgery refers to the process that assists in the removal of clouding of natural lens from the affected eye.

Iovance Biotherapeutics, Inc. today announced that Raj K. Puri, M.D., Ph.D., will join the Company as Executive Vice President, Regulatory Strategy and Translational Medicine.

MiMedx Group, Inc., a transformational placental biologics company, provided a recap of key 2021 accomplishments and outlined strategic milestones planned for 2022.

Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced that the Company will be participating in the H.C. Wainwright BioConnect 2022 investor conference, to be held virtually from January 10-13, 2022.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced Oxbryta® (voxelotor) tablets for oral suspension, a new dispersible, once-daily tablet dosage form recently approved by the U.S. Food and Drug Administration (FDA), is now available through GBT’s specialty pharmacy partner network in the United States.

Vyant Bio, Inc., an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system diseases.

4D Molecular Therapeutics (NASDAQ: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 4D-125 for treatment of patients with inherited retinal dystrophies due to defects in the RPGR gene, including X-linked Retinitis Pigmentosa (XLRP).

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the National Medical Products Administration (NMPA) has approved the CoreValve™ Evolut™ PRO TAVR system for the treatment of severe aortic stenosis (AS) for symptomatic patients in China who are at high or extreme risk for open heart surgery.